Arcosa walks into its Q1 2026 earnings call on a remarkable run — up 24% over the past month to $126.47, with the stock adding another 8.6% on Wednesday alone.
The price action dominates the setup. That one-day move is the standout feature heading into the print: the stock closed April at a level that now sits almost exactly in line with the consensus analyst price target of $127.25, effectively erasing any remaining upside implied by the Street in a single session. The last comparable analyst target raise came from DA Davidson in March, lifting to $125 from $120 — a target the stock has now blown through. The broader analyst direction has been constructive for well over a year, with Barclays initiating at Overweight in late 2024 and lifting its target to $115 by November. But at current prices, the consensus implies just 0.6% further upside, a paper-thin cushion heading into the release.
Short positioning tells a quieter story than the price action alone might suggest. Short interest has climbed roughly 18% over the past month to 2.7% of the free float — a meaningful increase in rate terms, though the absolute level remains modest. Days to cover are 5.25, and cost to borrow is a negligible 0.41%. Availability is comfortably wide, meaning there is no squeeze dynamic in the lending market. Options positioning has nudged more defensive into the print: the put/call ratio moved to 0.39, above its 20-day average of 0.33 and roughly 1.4 standard deviations elevated — a mild tilt toward protection, not outright alarm. The ORTEX short score of 37.6 is mid-range and has been stable, reinforcing that short sellers are building a position gradually rather than pressing aggressively.
The bull and bear debate now centres squarely on whether the valuation reset is warranted. The trailing P/E has expanded to 27.8x, up more than 6 points over the past 30 days, and EV/EBITDA has risen to 13.1x — both moving sharply in the stock's favour as the price ran. Q1 consensus revenue estimates point to roughly $621 million, with EBITDA near $100 million. Bears will note the EPS momentum factor ranks in just the 7th percentile over the past month, meaning forward earnings estimates have not kept pace with the stock. The EPS surprise rank of 77 provides some historical reassurance, but the last earnings reaction — a 14.8% single-day drop in February 2026 — is a reminder that the stock can move sharply when results miss the bar. Bulls, by contrast, will point to Arcosa's infrastructure-facing business mix, where demand visibility from public spending remains a tailwind.
T. Rowe Price is the most notable institutional mover in recent filings, adding 423,000 shares to become a nearly 3.7% holder. Insider activity has been routine — a cluster of March award grants followed by modest open-market sales around $105, well below where the stock trades today. The print will test whether the infrastructure demand story can justify a valuation that just re-rated almost 25% in a month.
See the live data behind this article on ORTEX.
Open ACA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
